Literature DB >> 17038032

Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease.

M Horstink1, E Tolosa, U Bonuccelli, G Deuschl, A Friedman, P Kanovsky, J P Larsen, A Lees, W Oertel, W Poewe, O Rascol, C Sampaio.   

Abstract

To provide evidence-based recommendations for the management of late (complicated) Parkinson's disease (PD), based on a review of the literature. Complicated PD refers to patients suffering from the classical motor syndrome of PD along with other motor or non-motor complications, either disease-related (e.g. freezing) or treatment-related (e.g. dyskinesias or hallucinations). MEDLINE, Cochrane Library and INAHTA database literature searches were conducted. National guidelines were requested from all EFNS societies. Non-European guidelines were searched for using MEDLINE. Part II of the guidelines deals with treatment of motor and neuropsychiatric complications and autonomic disturbances. For each topic, a list of therapeutic interventions is provided, including classification of evidence. Following this, recommendations for management are given, alongside ratings of efficacy. Classifications of evidence and ratings of efficacy are made according to EFNS guidance. In cases where there is insufficient scientific evidence, a consensus statement ('good practice point') is made.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17038032     DOI: 10.1111/j.1468-1331.2006.01548.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  41 in total

1.  Pharmacotherapy in Parkinson's disease: case studies.

Authors:  Tiago Mestre; Joaquim J Ferreira
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

2.  Behavioral disturbance in dementia.

Authors:  Abhilash K Desai; Lori Schwartz; George T Grossberg
Journal:  Curr Psychiatry Rep       Date:  2012-08       Impact factor: 5.285

Review 3.  Adenosine A2A receptor antagonists in Parkinson's disease: progress in clinical trials from the newly approved istradefylline to drugs in early development and those already discontinued.

Authors:  Annalisa Pinna
Journal:  CNS Drugs       Date:  2014-05       Impact factor: 5.749

4.  Tetrabenazine improves levodopa-induced peak-dose dyskinesias in patients with Parkinson's disease.

Authors:  L Brusa; A Orlacchio; A Stefani; S Galati; M Pierantozzi; C Iani; N B Mercuri
Journal:  Funct Neurol       Date:  2013 Apr-May

5.  Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses.

Authors:  Tiago A Mestre; Prakesh Shah; Connie Marras; George Tomlinson; Anthony E Lang
Journal:  Neurology       Date:  2014-03-21       Impact factor: 9.910

6.  Population in vitro-in vivo correlation model for pramipexole slow-release oral formulations.

Authors:  Elena Soto; Sebastian Haertter; Michael Koenen-Bergmann; Alexander Staab; Iñaki F Trocóniz
Journal:  Pharm Res       Date:  2009-12-29       Impact factor: 4.200

Review 7.  Drug-induced urinary retention: incidence, management and prevention.

Authors:  Katia M C Verhamme; Miriam C J M Sturkenboom; Bruno H Ch Stricker; Ruud Bosch
Journal:  Drug Saf       Date:  2008       Impact factor: 5.606

Review 8.  Neural stem cells could serve as a therapeutic material for age-related neurodegenerative diseases.

Authors:  Sarawut Suksuphew; Parinya Noisa
Journal:  World J Stem Cells       Date:  2015-03-26       Impact factor: 5.326

9.  Neuroticism and extraversion in association with quality of life in patients with Parkinson's disease.

Authors:  Tatiana Dubayova; Iveta Nagyova; Eva Havlikova; Jaroslav Rosenberger; Zuzana Gdovinova; Berrie Middel; Jitse P van Dijk; Johan W Groothoff
Journal:  Qual Life Res       Date:  2008-11-07       Impact factor: 4.147

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.